Siemens Healthineers Secures FDA Green Light for AI Imaging Suite as €13.9bn Refinancing Challenge Looms

Siemens Healthineers enters a pivotal week with its stock pinned near a 52-week low and a fresh regulatory win competing for attention against a €13.9bn refinancing burden that threatens to reshape the company's financial profile. The U.S. Food and Drug Administration has just cleared the entire Artis portfolio of interventional imaging systems — six configurations including floor, biplane, ceiling and Pheno variants — all powered by the new Optiq AI Imaging Chain. The deep-learning engine reduces noise in real time across fluoroscopy, angiography and other 2D modalities, delivering crisper visualisation for minimally invasive cardiology and neurology procedures.

Yet the share price remains stubbornly depressed. At €33.00, the stock has shed roughly 26% since the start of the year and sits more than a third below last summer's peak. Friday's close of €33.59 offered little relief. The market's scepticism stems squarely from the Diagnostics division, where structural headwinds in China have triggered a steep slide. In the second fiscal quarter, Diagnostics revenues slumped 6.5% on a comparable basis to €985m, with the adjusted EBIT margin collapsing to just 0.9%. Management now expects the unit's full-year revenue to shrink by up to 5% and its operating EBITDA margin to fall around five percentage points below last year's 7.7% level.

Group figures for the quarter showed €5.7bn in revenue, with comparable growth of 3.1% and adjusted earnings per share of €0.53. The overall outlook has been trimmed to comparable revenue growth of 4.5% to 5% and adjusted EPS of €2.20 to €2.30. Away from Diagnostics, the picture is brighter. Imaging expanded 6.1%, Precision Therapy rose 4.7% and the Varian oncology unit added 7.5%. Over the medium term, the company is targeting annual growth of 6% to 9% for the combined Imaging and Precision Therapy businesses.

Should investors sell immediately? Or is it worth buying Siemens Healthineers?

The FDA clearance strengthens the Advanced Therapies segment — a unit that is largely insulated from the China crisis — and underlines the technological progress being made. But the structural fix for Diagnostics has now moved centre stage. CEO Bernd Montag has initiated a legal separation of the division, keeping all options open from an external sale to continued operation as a standalone entity. CFO Jochen Schmitz confirmed that financial investors have expressed interest, though no formal talks are underway. Shareholders will vote on a direct demerger at the annual general meeting in February 2027. Parent Siemens AG, which currently controls roughly 67% of Healthineers, plans to transfer 30 percentage points of that stake directly to its own shareholders, surrendering its controlling majority. According to Reuters, Siemens aims to bring its holding below 20% over the medium term.

That exit comes at a cost. Barclays estimates that refinancing up to €13.9bn in loans — previously guaranteed by Siemens — will add €74m in interest expenses this fiscal year. Moody's has assigned an A3 rating with a stable outlook, but the overhang is significant. Tariff costs add another layer of strain, expected to climb from around €200m in fiscal 2025 to roughly €400m, though management aims to fully offset that impact by 2028.

Tuesday's investor meeting in New York will therefore be less about celebrating regulatory milestones and more about restoring confidence. The six-system FDA clearance is a genuine advance for the imaging business, but investors need credible answers on Diagnostics, the refinancing plan and the tariff path. How the market reconciles those competing pressures will determine whether the stock can finally climb off the floor.

Ad

Siemens Healthineers Stock: New Analysis - 18 May

Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Siemens Healthineers analysis...

en | DE000SHL1006 | SIEMENS | boerse | 69366254 |